These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 9123122)
1. Cyclosporin new oral formulation for early oral immunosuppressive therapy in liver transplant recipients. Winkler M; Haller GW; Oldhafer K; Bechstein WO; Maibücher A; Färber L; Ringe B; Neuhaus P; Pichlmayr R Transplant Proc; 1997; 29(1-2):544-6. PubMed ID: 9123122 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Cooney GF; Lum BL; Meligeni JA; Dunn SP Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222 [No Abstract] [Full Text] [Related]
3. [What significance has the C(2) value in the treatment with cyclosporin A?]. Pham VV; Stichtenoth DO; Frölich JC Dtsch Med Wochenschr; 2004 Mar; 129(13):706. PubMed ID: 15026970 [No Abstract] [Full Text] [Related]
4. Early use and oral absorption of cyclosporine neoral after liver transplantation. Kattner A; Ringe B; Haller GW; Kirchner G; Sewing KF; Winkler M Transplant Proc; 1998 Jun; 30(4):1422-3. PubMed ID: 9636576 [No Abstract] [Full Text] [Related]
5. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients. Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302 [No Abstract] [Full Text] [Related]
6. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Loss GE; Brady L; Grewal HP; Siegel CT; Mead J; Bruce DS; Cronin DC; Woodle ES; Newell KA; Thistlethwaite JR; Millis JM Transplant Proc; 1998 Jun; 30(4):1435-6. PubMed ID: 9636581 [No Abstract] [Full Text] [Related]
7. Area under the concentration curve values in pediatric liver transplant recipients on cyclosporin microemulsion formulation. Dunn SP; Kulinsky A; Falkenstein K; Pierson A; Chang CT; Cooney GF Transplant Proc; 1998 Aug; 30(5):1678-9. PubMed ID: 9723240 [No Abstract] [Full Text] [Related]
8. Safety and tolerability of Neoral in transplant recipients. Feutren G; Wong R; Jin J; Niese D; Mellein B Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193 [No Abstract] [Full Text] [Related]
9. A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients. Winkler M; Haller G; Oldhafer K; Bechstein WO; Kattner A; Maibücher A; Färber L; Ringe B; Christians U; Neuhaus P; Pichlmayr R Transplantation; 1996 Oct; 62(8):1063-8. PubMed ID: 8900302 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
11. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Trull AK; Tan KK; Tan L; Alexander GJ; Jamieson NV Transplant Proc; 1994 Oct; 26(5):2977-8. PubMed ID: 7940939 [No Abstract] [Full Text] [Related]
12. Effect of the transition from intravenous to oral dosing on cyclosporin-A trough concentrations in liver transplant patients. Maboundou CW; Paintaud G; Bresson-Hadni S; Mantion G; Miguet JP; Bechtel PR Ther Drug Monit; 1996 Jun; 18(3):310-4. PubMed ID: 8738775 [TBL] [Abstract][Full Text] [Related]
14. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB; Martin JE; Schroeder TJ; First MR Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291 [No Abstract] [Full Text] [Related]
15. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Schädeli F; Marti HP; Frey FJ; Uehlinger DE Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097 [TBL] [Abstract][Full Text] [Related]
16. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application? Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211 [No Abstract] [Full Text] [Related]
17. Microemulsion formulation of cyclosporine in pediatric liver transplantation. Alberti D; Wallemacq P; Falchetti D; de Ville de Goyet J; Rigamonti W; Panzali A; Sokal E; Otte JB; Reding R Transplantation; 1996 Feb; 61(3):512-4. PubMed ID: 8610371 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157 [No Abstract] [Full Text] [Related]
19. Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients. D'Agostino D; Gimenez M; Yamaguchi B; Glancszpigel R; Vinuesa F; Gamba M; Ciardullo M; de Santibaes E Transplantation; 1996 Oct; 62(8):1068-71. PubMed ID: 8900303 [TBL] [Abstract][Full Text] [Related]
20. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation. Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219 [No Abstract] [Full Text] [Related] [Next] [New Search]